The Australian Academy of Health and Medical Sciences elects the best and brightest minds in the field of medical and health sciences as Fellows.

Fellows are elected in recognition of their outstanding achievements and exceptional contributions to the sector. The Fellowship are acknowledged for their clinical, non-clinical, leadership, industry and research contributions.

About Fellowship with AAHMS

Find Fellows of the AAHMS

To find Fellows of our Academy either use the search form below or download the full list of current Fellows here.






Director of Serology, Virology and OTDS screening (SAViD). Chair Biosecurity Quality Assurance Program QAP
SEALS Department of Microbiology, NSW Health Pathology

William Rawlinson is a clinician scientist recognised internationally for translational research into cytomegalovirus, congenital malformation from infections, and viral diseases of immunosuppressed patients.  He established, and oversees, serology and virology clinical research programs, state-wide transplant donor screening, and national quality programs for serology and biosecurity.  He is conjoint professor at UNSW while holding an NHMRC Practitioner Fellowship.  His research has attracted $41 million in competitive funding and his 290 publications have an H-index of 52.  His contributions are recognised by an Order of Australia (AM) for services to medical sciences, Fenner prize, and the Australian Council on Healthcare Standards Gold medal.

Director and CEO
QIMR Berghofer Medical Research Institute

Professor Fabienne Mackay is an internationally renowned immunologist who has published over 138 highly cited research articles and reviews. Her h-index is 56 (12,396 citations). In 2012, she was awarded the Thomson Reuters Citation and innovation Award, and in 2014 a Trophy from the French ministry of foreign affairs for outstanding achievement in research and education as an expatriate. One of her many contributions has been the discovery of BAFF/BLyS as a key factor driving lupus, a breakthrough discovery which led to the development of a now FDA-approved BAFF inhibitor: the first new treatment for lupus in over 50 years.

Scientia Professor/NHMRC Senior Principal Research Fellow
The University of New South Wales

Richard Bryant is an internationally renowned authority in the field of mental health following traumatic events. Amongst his many world‐first achievements, Bryant’s development of assessment tools for identifying recently traumatized people who may subsequently develop PTSD has become the international gold standard in the field. Moreover, he was subsequently tasked with overseeing the new diagnostic guidelines for ‘acute stress disorder’ in the 2013 edition of the American Psychiatric Association’s diagnostic system (DSM‐5).  His outstanding profile is evidenced by prestigious research fellowships, senior executive roles in international professional organisations and Fellowship of the ASSA. He would be an influential Academy member.

Consultant Paediatrician
Children’s Health Queensland Hospital and Health Service

Professor Claire wainwright is the Head of Cystic Fibrosis (CF) services which provide state-wide services for around 420 children with CF across Queensland.  She also runs the respiratory service for the only national clinic caring for children with ataxia telangiectasia.  She has a long standing research interest in airway diseases, including bronchiolitis, asthma, cystic fibrosis and rare lung diseases.  Professor Wainwright conducted the first randomized trial of BAL-directed therapy to improve clinical outcomes in infants and young children with CF.  She has also been instrumental in the design and conduct of clinical trials that have brought ivacaftor and lumacaftor to the CF community.

Research Professor
Griffith University

Professor Cripps has made significant contributions to the delivery of health services, leadership in health academia and in research. He has led and implemented programs for the training of thousands of future of health professionals. His research has focused on the study of mucosal immunology and preventing respiratory infections. Professor Cripps’ efforts have brought together academics, researchers and clinicians, to ensure that research is relevant to global health issues, informed by the needs of the community and focused on translation into practice. In 2015 he was made an officer of the Order of Australia for his distinguished service to health.


Vale Allan Cripps, December 2022.

Deputy Director and Head, Developmental and Stem Cell Biology Division
Victor Chang Cardiac Research Institute

Richard Harvey is a pioneer of the molecular era of heart development and congenital heart disease (CHD) research, and has contributed significantly to cardiac regeneration biology.  His discovery of the homeodomain transcription factor Nkx2‐5 provided the key entry point for molecular dissection of heart development and CHD in humans.  His work defined new patterning principals that govern heart development and the many layers of regulation in heart formation and disease.  His studies have redefined our vision of the developing heart and opened the doors to systems level analysis, and cardiac bioengineering and stem cell biology.

Senior Deputy Director; Laureate Professor
The Florey Institute of Neuroscience and Mental Health

Colin Masters’ work over the last 35 years is widely acknowledged as having had a major influence on Alzheimer’s disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the Aβ amyloid protein which causes Alzheimer’s disease. Masters has continued to identify and develop effective rational therapeutic and diagnostic strategies for disease modification, perhaps even prevention. Masters’ publishes on average 30 papers a year, serves on 19 Editorial Boards, is an advisory member of 17 research organizations and continues to lecture widely, both nationally and internationally.

Executive Director
Children’s Cancer Institute

Professor Michelle Haber is a world leader in the field of childhood cancer research. She has made fundamental discoveries in the area of drug resistance in neuroblastoma which have had major impact on the global research community. She has translated these discoveries into new therapeutics that are currently being clinically tested and has developed into a key leader of the Australian biomedical research community.

Co Leader, Hematological Malignancies Program
St Jude Children’s Research Hospital, South Australian Health and Medical Research Institute

Charles Mullighan is an academic haematologist who has devoted his research career to defining the genetic basis of acute lymphoblastic leukaemia, a leading cause of childhood cancer death. His work has resulted in multiple seminal studies that have transformed our understanding of this disease and related tumours. He is regarded as an international leader in this research and has major leadership positions in the hematology community. His work has had major clinical impact by identifying new genetic markers that assist diagnosis and prediction of prognosis, and by identifying new targets for intervention with targeted
therapies in high risk leukaemia.

Executive Director Clinical Innovation, Riverland Mallee Coorong LHN; Emeritus Professor, Flinders University
SA Health

Professor Paul Worley is a rural doctor and Emeritus Professor at Flinders University. His ground‐breaking work in the science of rural community based medical education, and its impact on addressing the maldistribution of doctors for rural and underserved areas, has changed the face of medical education and rural medical workforce policy nationally and internationally. His leadership of junior doctor training in general practice has transformed the transition from medical school to post‐graduate training for general practice. He is a past President of the Rural Doctors Association of SA, a previous Vice President of ACRRM and consultant to the WHO.

Our Fellows sit at the heart of everything we do. They represent Australia’s leading minds in health and medical sciences, having been recognised for their clinical, non-clinical, leadership, industry and research contributions.

To be considered for election to the Academy’s Fellowship, a candidate must show exceptional professional achievement in a field related to health and/or medicine.

Fellows contribute to the projects and activities of the Academy and must be willing to be active participants.

Successful Fellowship candidates will have shown:

  • Outstanding leadership in their field.
  • Significant and ongoing involvement with issues of health care, prevention of disease, education, research, and health services policy and delivery.

Candidates for Fellowship should meet the following criteria:

  • National and International recognition for excellence in health and medical science
  • Significant, sustained and ongoing contributions to advance health and medical science in Australia (relative to opportunity)
  • Contribution to the profession through leadership and mentorship
  • Raised public understanding and promoting health and medical science in the broader community

Download criteria for Fellowship

Each year, current Fellows of the Academy are invited to nominate up to four new candidates who meet the criteria and fulfil the required expectations.

Nominations by a Fellow of two new candidates must ensure that at least one nomination is a woman. Nominations by a Fellow of four new candidates must ensure that at least two nominations are women.

How to make a nomination

Fellows wishing to nominate a candidate for Fellowship should contact the secretariat to confirm candidate eligibility and receive and instructions on how to submit the completed nomination documentation online. 

Fellows wishing to nominate a candidate for a Corresponding Fellowship should contact the secretariat for more information.

Secretariat contact details
Email: [email protected]

Phone: 07 3102 7220

Nomination guidelines for ordinary Fellowship

October 2023
Newly elected Fellows of 2023 are inducted at the Annual Meeting.

18 September 2023- 30 November 2023
Nominations are invited from existing Fellows until the closing date of 30 November.

December 2023
Nominations allocated to Selection Committees.

January – April 2024
Referees’ reports sought.

Early May 2024
Selection Committees meet to consider nominations and provide final recommendations to the Council.

Early-to-mid-July 2024
Council meets to finalise recommendations.

Late July 2024
Full Fellowship invited to comment on recommended new fellows.

August 2024
Election results are shared with proposers and candidates (under embargo).

October 2024
Newly elected Fellows of 2024 inducted at the Annual Meeting.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.